Nature Communications

Neoadjuvant chemoradiotherapy plus sintilimab in proficient mismatch repair locally advanced rectal cancer with intermediate/high-immunoscore (SILAR): a single-arm phase II trial

2026-01-21

Full text

DOI https://doi.org/10.1038/s41467-025-65162-8